Clinical trials: IgAN
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
IgA Nephropathy (IgAN), Membranous Nephropathy
Raman Spectroscopy Diagnosis of Kidney Diseases
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental…
- Conditions
- IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06760845
- Testing
- Imaging Time
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zunsong Wang
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
IgA Nephropathy, Glomerular Diseases
Biomarkers for the Progression of IgA Nephropathy
IgA nephropathy (IgAN) is the most prevalent primary glomerular disease worldwide and an important cause of end stage renal disease.
- Trial name
- NCT02529722
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Istanbul University
Glomerulonephritis, IGA, Peripapillary Crescent
A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with active pathological changes,including crescents,necrosis and…
- Conditions
- Glomerulonephritis, IGA, Peripapillary Crescent, Necrosis, Steroid Nephropathy
- Trial name
- NCT02160132
- Testing
- Methylprednisolone(intravenously in the 1st-2nd-3rd month ), Methylprednisolone(intravenously in the 1st-3rd-5th month)
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Glomerulonephritis, IGA, Kidney Diseases
Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
Crescentic IgA nephropathy (CreIgAN) has a poor prognosis despite aggressive immunosuppressive therapy. The efficacy of plasma exchange (PE) in CreIgAN is not well defined.
- Conditions
- Glomerulonephritis, IGA, Kidney Diseases, Acute Renal Insufficiency, Rapidly Progressive Glomerulonephritis
- Trial name
- RESCUE (NCT02647255)
- Testing
- Plasma Exchange (PE), Methylprednisolone pulse
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking University First Hospital
IgA Nephropathy
SodiUm Restriction by Behavioral Intervention
The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction by mean of a new healthcare approach in patients with immunoglobulin A nephropathy.
- Trial name
- SURBI (NCT04805047)
- Testing
- education and monitoring
- Where
- China
- Volunteers
- 142 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Glomerulonephritis, IGA
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
- Trial name
- NCT02232776
- Testing
- Losartan
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Seoul National University Hospital
IgA Nephropathy
The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated…
- Trial name
- MAIN (NCT01854814)
- Testing
- Mycophenolate mofetil, Losartan
- Where
- 3 sites in China
- Volunteers
- 238 people
- Sponsor
- Fan Fan Hou
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
IgA Nephropathy
A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy
This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China.
- Trial name
- NCT01538433
- Where
- China
- Volunteers
- 603 people
- Sponsor
- Guangdong Provincial People's Hospital
Autoimmune Diseases, Systemic Lupus Erthematosus
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
this is an investigator-initiated trial aimed at evaluating the efficacy and safety of anti-CD19/BCMA CAR-NK Cells in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
- Trial name
- NCT06792799
- Testing
- anti-CD19/BCMA CAR NK cells (KN5601)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Glomerulonephritis, IGA, Renal Insufficiency, Chronic
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the poor treatment effect in advanced patients, it is still the main cause of maintenance dialysis.
- Trial name
- NCT04020328
- Testing
- Leflunomide 20 mg+prednisone 0.5mg/kg/d
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shenzhen Second People's Hospital
IGA Nephropathy
"Steroids and Azathioprine Versus Steroids Alone in IgAN"
In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant.
- Trial name
- NCT00755859
- Testing
- steroids plus azathioprine, steroids
- Where
- 28 sites in Italy, Switzerland
- Volunteers
- 206 people
- Sponsor
- A. Manzoni Hospital
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy
Longterm Renal Oucomes of STOP-IgAN Trial Participants
IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis in the Western world. Although most IgAN patients take a benign longterm course, about 20-30% progress to end-stage renal disease (ESRD) over 20…
- Trial name
- NCT03488368
- Testing
- observation
- Where
- Germany
- Volunteers
- 148 people
- Sponsor
- RWTH Aachen University
IGA Nephropathy
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy
This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of reh-acteoside therapy for patients of IgA nephropathy.
- Trial name
- NCT02662283
- Testing
- Prednisolone, Reh-acteoside
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Sun Yat-sen University
Glomerulonephritis, IGA
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN.
- Trial name
- NCT00378443
- Testing
- prednisone + Inhibace/Cozaar, Inhibace/Cozaar
- Sponsor
- Peking University